The NCI Formulary is a public-private partnership between the NCI and pharmaceutical and biotechnology companies with the purpose of providing NCI-designated Cancer Center investigators with rapid access to agents or combinations of agents for cancer clinical trial use. More…
NCI Experimental Therapeutics (NExT) Program
The NCI Experimental Therapeutics (NExT) Program
accepts proposals three times per year to facilitate
milestone-driven progression of new anticancer drugs
and imaging agents towards clinical evaluation and
registration. More…
Opportunities in Precision Medicine
On January 30, 2015, President Obama unveiled details
about the Precision Medicine Initiative, a bold new research effort to revolutionize how we improve health and treat
disease. Precision medicine uses information about the
genes, proteins, and other features of a person’s cancer to diagnose or treat their particular disease. More…
DCTD PROGRAMS
Provides statistical, computational, and systems biology analyses
Funds specimen resources and research to characterize tumors
Evaluates imaging in diagnosis, disease staging, and treatment monitoring
Assesses new anticancer agents, radiation treatments, and surgical methods
Funds drug discovery and development and provides related services
Funds novel radiotherapy research
Integrates scientific advancements in the understanding of the biology of human cancer
Improves the quality of cancer research on complementary and alternative modalities
DCTD ACTIVITIES
Conducts early-phase clinical trials of novel cancer treatment agents
Defines approaches to cancer treatment based on molecular characterization and biomarker assay development
Provides NCI-designated Cancer Center investigators with rapid access to agents for cancer clinical trial use via public-private partnerships
Maximizes knowledge of tumor biology and resources to facilitate rapid initiation and completion of cancer clinical trials
Supports the most promising new drug discovery and development projects
Promotes research and development of quantitative imaging methods to measure tumor response to therapies in clinical trials
Research Excellence
Promotes collaborative, interdisciplinary, translational research leading to new approaches for prevention, early detection, diagnosis, and treatment of cancer
Message from the DCTD Director:
The Division of Cancer Treatment and Diagnosis (DCTD) focuses its activities on developing novel diagnostics and therapies for cancer. DCTD staff members, along with colleagues throughout the National Cancer Institute (NCI), academia, and industry, are working to generate a seamless pipeline of biomarkers and therapeutics that runs the gamut from initial efforts in drug discovery through late-stage clinical trials. More…